表紙
市場調査レポート

Beijing Minhai Biotechnology Co., Ltd :製品パイプライン分析

Beijing Minhai Biotechnology Co., Ltd - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 315709
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
Beijing Minhai Biotechnology Co., Ltd :製品パイプライン分析 Beijing Minhai Biotechnology Co., Ltd - Product Pipeline Review - 2015
出版日: 2015年04月22日 ページ情報: 英文 46 Pages
概要

Beijing Minhai Biotechnology Co., Ltd は、感染症の予防と治療のためのワクチンを研究開発し、製品化して人々の健康に貢献することを目指しているバイオテクノロジー企業です。

当レポートでは、Beijing Minhai Biotechnology Co., Ltd における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Beijing Minhai Biotechnology Co., Ltdの基本情報

  • Beijing Minhai Biotechnology Co., Ltdの概要
  • 主要情報
  • 企業情報

Beijing Minhai Biotechnology Co., Ltd :R&Dの概要

  • 主な治療範囲

Beijing Minhai Biotechnology Co., Ltd :パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • 併用療法モダリティ
  • パートナー製品
    • パートナー製品/併用療法モダリティ

Beijing Minhai Biotechnology Co., Ltd :パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 登録前の製品/併用療法モダリティ
    • 第III相にある製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ

Beijing Minhai Biotechnology Co., Ltd :薬剤プロファイル

  • pneumococcal polysaccharide vaccine (23-valent)
  • hepatitis A vaccine
  • hepatitis B vaccine
  • meningococcal conjugate vaccine serogroups A, C, Y and W135
  • cholera vaccine (trivalent)
  • diphtheria + tetanus + pertussis (acellular) vaccine
  • haemophilus influenzae conjugate vaccine type B
  • hepatitis A + hepatitis B vaccine
  • influenza vaccine (split virion)
  • meningococcal conjugate vaccine (tetravalent)
  • meningococcal polysaccharide vaccine (tetravalent)
  • pneumococcal conjugate vaccine 13-valent
  • rabies vaccine MRC-5
  • enterovirus 71 vaccine
  • herpes vaccine
  • human papillomavirus vaccine (tetravalent)
  • influenza vaccine H1N1
  • meningococcal vaccine serogroup B
  • pneumococcal conjugate vaccine (15-valent)
  • rotavirus vaccine (pentavalent)

Beijing Minhai Biotechnology Co., Ltd :パイプライン分析

  • 投与経路別
  • 分子タイプ別

Beijing Minhai Biotechnology Co., Ltd :本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06908CDB

Summary

Global Markets Direct's, 'Beijing Minhai Biotechnology Co., Ltd - Product Pipeline Review - 2015', provides an overview of the Beijing Minhai Biotechnology Co., Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Beijing Minhai Biotechnology Co., Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Beijing Minhai Biotechnology Co., Ltd including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Beijing Minhai Biotechnology Co., Ltd's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Beijing Minhai Biotechnology Co., Ltd's pipeline products

Reasons to buy

  • Evaluate Beijing Minhai Biotechnology Co., Ltd's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Beijing Minhai Biotechnology Co., Ltd in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Beijing Minhai Biotechnology Co., Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Beijing Minhai Biotechnology Co., Ltd and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Beijing Minhai Biotechnology Co., Ltd
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Beijing Minhai Biotechnology Co., Ltd and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Beijing Minhai Biotechnology Co., Ltd Snapshot
    • Beijing Minhai Biotechnology Co., Ltd Overview
    • Key Information
    • Key Facts
  • Beijing Minhai Biotechnology Co., Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline Products Glance
    • Beijing Minhai Biotechnology Co., Ltd - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Beijing Minhai Biotechnology Co., Ltd - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Beijing Minhai Biotechnology Co., Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Beijing Minhai Biotechnology Co., Ltd - Drug Profiles
    • pneumococcal polysaccharide (23-valent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diphtheria + tetanus + pertussis (acellular) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • haemophilus influenzae [serotype B] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis A vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meningococcal [serogroups A, C, Y and W135] (tetra valent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meningococcal polysaccharide [serogroups A, C, Y and W135] (tetravalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rabies vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cholera (trivalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis A + hepatitis B vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis B vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza (split virion) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pneumococcal (13-valent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • enterovirus 71 vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • herpes zoster vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • human papillomavirus (tetravalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • influenza [H1N1] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • measles + rubella + varicella vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • meningococcal [serogroup B] vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • mumps vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rotavirus (pentavalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • varicella vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline Analysis
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline Products by Route of Administration
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline Products by Molecule Type
  • Beijing Minhai Biotechnology Co., Ltd - Dormant Projects
  • Beijing Minhai Biotechnology Co., Ltd - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Beijing Minhai Biotechnology Co., Ltd, Key Information
  • Beijing Minhai Biotechnology Co., Ltd, Key Facts
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Indication, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Stage of Development, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Monotherapy Products in Pipeline, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Combination Treatment Modalities in Pipeline, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Partnered Products in Pipeline, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Partnered Products/ Combination Treatment Modalities, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pre-Registration, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Phase III, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Phase I, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Preclinical, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Route of Administration, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Molecule Type, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Dormant Developmental Projects,2015

List of Figures

  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Top 10 Indication, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Stage of Development, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Monotherapy Products in Pipeline, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Combination Treatment Modalities in Pipeline, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Top 10 Route of Administration, 2015
  • Beijing Minhai Biotechnology Co., Ltd - Pipeline by Top 10 Molecule Type, 2015
Back to Top